Clinical Trial Update: Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria [NA]

View source ↗

Summary

This clinical trial evaluated Mucomyst (N-acetylcysteine) to reduce oxidative stress in diabetics with proteinuria; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Proteinuria

Drugs mentioned

• Mucomyst (N-acetylcysteine)

Snippet

Sponsor: US Department of Veterans Affairs | Conditions: Diabetes, Proteinuria | NA | Status: COMPLETED